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Background: Two of the commonest chronic diseases experienced by older people in the general population are
cardiovascular diseases and osteoarthritis. These conditions also commonly co-occur, which is only partly explained
by age. Yet, there have been few studies investigating specific a priori hypotheses in testing the comorbid
interaction between two chronic diseases and related health and healthcare outcomes. It is also unknown whether
the stage or severity of the chronic disease influences the comorbidity impact. The overall plan is to investigate the
interaction between cardiovascular severity groups (hypertension, ischaemic heart disease and heart failure) and
osteoarthritis comorbidity, and their longitudinal impact on health and healthcare outcomes relative to either
condition alone.
Methods: From ten general practices participating in a research network, adults aged 40 years and over were
sampled to construct eight exclusive cohort groups (n = 9,676). Baseline groups were defined on the basis of
computer clinical diagnostic data in a 3-year time-period (between 2006 and 2009) as: (i) without cardiovascular
disease or osteoarthritis (reference group), (ii) index cardiovascular disease groups (hypertension, ischaemic heart
disease and heart failure) without osteoarthritis, (iii) index osteoarthritis group without cardiovascular disease, and
(vi) index cardiovascular disease groups comorbid with osteoarthritis. There were three main phases to longitudinal
follow-up. The first (survey population) was to invite cohorts to complete a baseline postal health questionnaire,
with 10 monthly brief interval health questionnaires, and a final 12-month follow-up questionnaire. The second
phase (linkage population) was to link the collected survey data to patient clinical records with consent for the
3-year time-period before baseline, during the 12-month survey period and the 12 months after final questionnaire
(total 5 years). The third phase (denominator population) was to construct an anonymised clinical data archive for
the study five year period for the total baseline cohorts, linking clinical information such as diagnosis, prescriptions
and referrals.
Discussion: The outcomes of the study will result in the determination of the specific interaction between
cardiovascular severity and osteoarthritis comorbidity on the change and progression of physical health status in
individuals and on the linked and associated clinical-decision making process in primary care.
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As people get older, they are more likely to experience a
chronic disease, such as cardiovascular disease (CVD) or
osteoarthritis (OA), and many will experience two or
more chronic diseases at the same time [1]. With in-
creasing life spans, each individual is more likely to
experience multiple chronic diseases. Yet, in the day-to-
day management of patients, the focus has often been
on single chronic disease [2]. Such approaches do not
acknowledge or address the common experience of older
populations with multiple chronic diseases such as CVD
and OA. Implications for the impact on health care and
health care systems lie, for example, in the variations in
the clinical decision-making process as exemplified by
referrals [3] and in mortality outcomes [4], which could
be explained by the presence of multiple chronic dis-
eases in the same individual. It has been argued that the
management of single diseases may distort the provision
of good health care by not addressing the potential inter-
actions of different conditions and therefore not appro-
priately assessing the management of each chronic
illness in the real clinical situation [5]. Consideration of
potential patterns of care in patients with comorbidity
requires a broader perspective on management and the
clinical pathways, and alternative approaches are
required to address this problem [6]. From an inter-
national perspective, in an ageing European population,
this issue is set to become an increasing public health
priority. Current estimates range up to 30 million
European sufferers with two or more chronic diseases, with
further increases likely as the number of older Europeans
expands by an estimated 30% in the next 25 years [7].
Two of the commonest chronic diseases experienced
by older people in the general population are CVD and
OA [8]. Cardiovascular disease, shares many of the
chronic disease characteristics shown by OA, and is an
important cause of disability as well as mortality. A
range of studies have shown that CVD is associated with
poor physical health, and this relationship influences
management progression and health care outcomes. For
example, people with poor physical health are likely to
report greater CVD health needs [9], the progression of
CVD symptoms is likely to be associated with poor
physical health [10] and this in consequence is likely to
lead to higher hospital admissions and mortality [11]. In
a similar pattern to OA, co-existing depression adversely
influences symptoms of CVD and is more likely to be
associated with poor physical health [12]. Specific stud-
ies have also shown that poor physical health is asso-
ciated with CVD that range from hypertension, atrial
fibrillation, angina, myocardial infarction to heart failure.
Some studies indicate that poor health in hypertension
is unexplained by socio-demographic factors or comor-
bidity [13], in atrial fibrillation is dependent on theseverity of symptoms [14], in angina patients is asso-
ciated with depression and anxiety [15], and in myocar-
dial infarction or heart failure is associated with poor
health care outcomes [16,17].
Osteoarthritis is the most frequent reason for
restricted activity in daily life [18] and has a high im-
pact on health care use and costs [19], both in hos-
pital (for example, joint replacements [20]) and in
primary care in relation to consultations and drug use
[21]. The prevalence of many other disabling condi-
tions also rises with age, and some common chronic
conditions can be found alongside OA, including CVD
[22]. We have previously shown that there are specific
associations in OA sufferers in general practice [23]
and that the combination of OA and comorbidity is
associated with much poorer physical health [24]. Sev-
eral studies have shown that OA and specific CVD are
associated together and this co-occurrence is independ-
ent of age [25,26]. Explanations for this finding include
pathologic links, similar and shared risk factors or inter-
mediary links, such as drugs (anti-inflammatories). In
addition to adverse mortality outcomes, previous OA
studies have also shown that people with CVD comor-
bidity have poor quality of life, and that co-existing
conditions such as depression can influence similar
outcomes [27,28].
In primary care, where multiple morbidity is the rule
rather than the exception [29,30], general practitioners
and primary care by definition deal with many different
morbidities presented by the same individual. As each
encounter contributing to multiple morbidity is rou-
tinely recorded during consultations and subsequently
in historical records, so a catalogue of health states
emerges through which an individual passes over time.
Such health events might be linked to each other [31],
because they represent overlapping syndromes [32] or
are a result of shared causes or mechanisms, and their
interactions might help to explain different patterns in
health course or progression. Studies of multiple mor-
bidity in primary care, based on a limited number of
empirically selected chronic conditions, have shown
that it is negatively associated with overall health [33]
and that it is associated with increased referral to sec-
ondary care and increased health care costs [1,34].
Whilst, studies of the association between specific
chronic diseases and overall health have been com-
pleted, especially in relation to changes within interven-
tion studies, very few studies have examined the
patterns of change in health that leads to consultation
[35] and in those with specific dual chronic diseases at
the same time. How comorbidity influences short and
longer-term health status in CVD or OA, how it causes
changes in health status, and how it influences health
care management decisions is unknown.
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be spectrum of different disease categories for each in-
dividual chronic disease. So for example, the term ‘CVD’
encapsulates a spectrum ranging from hypertension to
chronic congestive heart failure as outlined, and ‘OA’
encapsulates a spectrum of joint-specific problems. In
each spectrum, each stage implicitly carries the notion of
the process of disease severity related to a specific out-
come. For example, in people with OA, impact on mobil-
ity will be dependent on the joint site and whether there
is pain with or without radiographic change, whereas, the
stage of CVD will determine outcomes, such as health
status and mortality. In the course of chronic disease de-
velopment in populations, it is the stages within each dis-
ease process that offers one definition of ‘severity’.
Studies, for example, in the CVD field, suggest that the
lifetime risk of different CVD varies with age and the
related risk factors [36-38]. So instead of simply using
broad disease categories, the spectrum of CVD ‘severity’
potentially offers an empirical way of exploring the dis-
ease gradient to investigate whether the interaction be-
tween two individual chronic diseases and its impact on
health is over and above that which we might expect
from simply combining the individual effects.
Using an empirically defined order of disease severity
we intend to use hypertension, ischaemic heart disease
(angina or myocardial infarction) and heart failure as
indicators of CVD severity with comorbid OA defined
as a single broad category. In this study we propose to
investigate the specific interaction of CVD severity and
OA comorbidity on:
(i) the progression of physical health (with the null
hypothesis: that the adverse influence on physical
health is the same for CVD and comorbid OA
compared to those with either index condition
alone), and
(ii) the associated clinical decisions in consulting adult
general practice populations aged 40 years and over
compared to consulters with either condition alone
or without either condition (with the null
hypothesis: that clinical decisions are the same for
CVD and comorbid OA compared to those with
either index chronic disease).
Methods
Setting
Our study will be carried out in ten general practices,
from North Staffordshire, Stoke-on-Trent and Cheshire.
These practices are part of a local research network, the
Primary Care Musculoskeletal Research Consortium.
These practices, supported by the Primary Care
Research West Midlands North (PCR WMN) network,
cover a wide range of socio-economic groups and includespractices that have actively participated in routine collec-
tion of clinical data using computer records for the pur-
poses of epidemiological study. Clinical information
relating to all morbidity and drug therapies is recorded
using standard classifications of Read codes [39] and BNF
(British National Formulary) respectively [40]. Ethics
permission was sought and given by the Cheshire
Research Ethics Committee (REC ref no: 09/H1017/40).
Study population
The cohort study is based on the recruitment of four main
groups aged 40 years and over who have either a record
or consultation for: (i) No CVD or OA (reference); (ii)
CVD without OA; (iii) OA without CVD and (iv) CVD
and OA (comorbid cohort). The sampling of these groups
from the ten general practices was in a three-year period
beginning November 2006 and ending January 2010.
Identifying cohort samples
CVD cohorts: Using the CVD registers and historical
information, all adults aged 40 years and over who had
a record (main Read code Chapter G: “Cardiovascular
system diseases”) and on active registration at the end
of the 3-year study time-period will be identified.
Cohorts will then be based on the three CVD severity
categories of hypertension (Read and daughter codes
beginning with G20), ischaemic heart disease (Read and
daughter codes beginning with G3.) and heart failure
(Read and daughter codes beginning with G58 and
heart failure codes related New York Heart Association
(NYHA) classification), as these conditions are cur-
rently part of the national Quality Framework of clin-
ical recording, a means by which General Practitioners
(GP) are reimbursed as part of chronic disease manage-
ment. The CVD groups will be organised into three ex-
clusive severity groups, which means that allocation to
a cohort group will be based on the most severe cat-
egory e.g. if an individual had consulted for hyperten-
sion and heart failure, they would be in the heart
failure cohort. Previous studies have indicated that the
recording quality of such information is likely to be
high [41,42]. These three cohorts will be separated into
two sub-groups of (i) patients who had not consulted
for OA in the same time period (index CVD cohort)
and (ii) patients who had also consulted for OA in the
same time period (comorbid cohort). All those in the
three CVD severity groups who had comorbid OA
were sampled, as were those with heart failure or is-
chaemic heart disease but no OA. However, those with
hypertension but without OA were randomly sampled
(stratified by practice) given the high prevalence of this
group (see Sample size).
OA cohort: Using the general practice records for the
same time period (2006–2010), all adults aged 40 years
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have a historical record or consultation for OA (Read
and daughter codes beginning with N05, and codes
related to OA joint replacement (7 K2 or 7 K3)) will be
identified. This cohort group will be exclusive of those
patients who had also consulted for any CVD-related
diagnosis (as stated above) in the same time period.
Non-index cohort: Using the general practice records
for the same time period (2006–2010), a random sample
stratified by practice of all adults aged 40 years and over
without a historical record or consultation for the study
specific CVD and OA codes will be identified. This sam-
ple will provide a random reference group for the other
main cohort categories.
Data collection
There are 3 phases to the study data collection. The first
phase (survey population) will use postal questionnaires
to obtain self-reported health information at baseline,
monthly interval and 12-month follow-up. The second
phase (linkage population) will link the survey data to
consultation data, for patients who will give written con-
sent to access their clinical records from general practice
in the baseline questionnaire. The third phase (denomin-
ator population) will construct an anonymised database
for the whole cohort for the total five-year time-period.
So the denominator cohort constitutes the whole sample
from which the survey sample will be drawn. The de-
nominator sample will provide the basis for a distinct
cohort sample in its own right, as well as addressing se-
lection comparisons between people who took part in3-year and historical GP records 
Reference: Without CVD or OA 
3 Index CVD groups without OA 
Index OA group without CVD  
3 CVD comorbid groups with OA 
P
I
L
O
T
Baseline main 
questionnaire (Q1)  
General measures 
Cardiovascular measures 
Pain and OA measures 
Lifestyle measures 
Socio-demographic
Consent to monthly survey 
Consent to record review 
review to identify cohorts   :
Figure 1 2C study design.the survey and those who did not, and people who gave
consent to record review and who did not.Phase 1: Survey population
Overall, study participants will be invited to complete
12 questionnaires – baseline and 12-month follow up,
and between these time-points, 10 monthly short-
interval questionnaires (Figure 1). A pilot study in one
practice on 500 patients was carried out to test the
feasibility of sampling and testing of the questionnaire
methods.Baseline survey
The identified sampled cohorts will be sent a baseline
questionnaire (Q1), which will include generic and
specific-health measures (Table 1). Measures have been
identified on the basis of the primary focus on CVD and
OA diseases and other specific measures selected on the
basis of conceptual links between the disease and out-
come of interest in the follow-up phase.
For the primary outcome of interest, we will use the
Short-Form-12 (SF-12) (version 2) health survey as a
generic measure of physical health, specifically the Phys-
ical Component Summary (PCS) score [43]. We will also
include an assessment of physical activity [44] and Hos-
pital Anxiety and Depression (HAD) questionnaire will
be included as a measure of psychological status, that
influences both CVD and OA [45].
The CVD-specific measures will include the: Seattle
Angina Questionnaire [46], Kansas City Cardiomyopathy12 months
12-month Follow-up 
questionnaire (Q12) 
(Repeat main questionnaire) 
10 monthly-short 
questionnaires 
Table 1 Comorbidity Cohort (2C) study measures
Survey measures
Data source Factors Baseline & 12-month follow-up Short monthly**
Clinical records 8 disease cohorts • Read code classification*
Consultation comorbidity • Kadam severity classification
Blood tests & investigations • Read code classification*
Drugs prescribed • British National Formulary (BNF)
Referrals • Read code classification*
Survey data General measures • Short form 12 (SF-12) health survey • SF-12
• Short form 36 (SF-36) health survey – Q2 only • SF-36, Q2
• EuroQol (EQ-5D)
• Hospital Anxiety and Depression (HAD) scale
• Medical Outcomes Study (MOS) - Sleep Scale • Qs 1 & 2 only
• Functional Assessment of Chronic Illness (FACIT) – • Qs 5 & 6 only
Fatigue
• Brief Illness Perception Questionnaire (B-IPQ)
• Social Networks
Cardiovascular measures • Seattle Angina Questionnaire (SAQ), UK version • Qs 2 & 3 only
• Kansas City Cardiomyopathy Questionnaire (KCCQ) • Qs 3 & 7 only
• Rose Angina Questionnaire
• Palpitations (based on [50]) • Q1 only
• Vertigo Severity Scale (VSS) • Q1 only
Pain and OA measures • Pain manikin, pain frequency & pain intensity • Pain frequency
• Knee Injury & Osteoarthritis Outcome Score (KOOS) –
Physical Function Shortform
• Hip Injury & Osteoarthritis Outcome Score (HOOS) –
Physical Function Shortform
Lifestyle • Body Mass Index (BMI), Alcohol, Smoking
• Short Questionnaire to Assess Health Enhancing • Qs 2a, 2c, 2e only
Physical Activity (SQUASH)
Other • Eyesight/hearing
• Body shape
Survey & clinical records Socio-demographic • Age, Gender, Deprivation
*Read code classification is a standard clinical coding system used in British general practice; **question numbers refer to the original questionnaire.
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symptoms of palpitations [49] and dizziness [50].
The OA-specific measures will include the: Knee injury
and Osteoarthritis Outcome Score (KOOS – physical
function component) [51], Hip injury and Osteoarthritis
Outcome Score (HOOS – physical function component)
[52], pain scale, pain manikin [53], joint pain, and other
links previously reported in chronic disease literature in
relation to the symptoms of tiredness [54] and sleep [55].
Survey participants will also be requested for consent
to the monthly short-interval questionnaires and for per-
mission to the subsequent review of their clinical
records. Participants will be “tagged” in their general
practice registers as ‘2C’ study participants.Measurement of health in the 12-month follow-up period
With baseline consent, participants will be sent 10
monthly short-interval questionnaires (4 pages), including
the SF-12, pain measures and CVD symptom measures.
At the end of the study period, all study participants
will be sent a 12-month follow-up postal questionnaire
(Q12) using the same measures as used in the baseline
survey.
Phase 2: Survey-consultation linkage population
The linked consultation data covers a total five-year
time-period, for 3 years before the baseline survey,
12 months of the survey, and the 12 months after the
full follow-up survey. We will measure the clinical
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vey cohort follow-up. Using the same study samples for
both phases allows the linkage of the self-reported health
status, morbidity and the decision process experienced
by that individual patient in the 12-month period.
After the completion of the survey phase, the clinical
record data for cohort groups will be downloaded with
prior patient consent. Clinical decisions in consenting
patients will be measured following the baseline survey
on the basis of: (i) drug treatment changes (new, repeat,
dose, type), (ii) investigations such as blood tests or
X-rays, (iii) referrals (in-practice and external, investiga-
tion or second-opinion) or (iv) no change in any of these
measures. Drug use will be measured on the basis of
new index-related treatments (i.e. analgesia for OA and
CVD-related therapies), or change in doses used for
those on pre-existing drug treatments. Investigations will
cover index-specific indications, cardiological (e.g. Elec-
trocardiogram (ECG), Cholesterol) or rheumatological
(e.g. X-Rays). Referrals will include those relevant to the
index conditions (i.e. physiotherapists and allied thera-
pists, rheumatologists, orthopaedics and cardiologists)
and all other referrals. Other measurements for the
cohorts will include all other comorbidity using the
Kadam severity classification [56,57], specific morbidities
such as cerebrovascular disease and peripheral arterial
disease, and co-drug therapies used.
Phase 3: Anonymised denominator population
Phase 1, survey population method is defined by the
responders who take part in the study, phase 2, the
survey-consultation method is subject to the consenters
who will give permission for this link to occur. There-
fore, phase 3 will focus on the total cohort denominator
population and the anonymised clinical data within the
medical records of each individual patient to allow
methodological assessment of response biases in the co-
hort samples. Patients who explicitly stated to their gen-
eral practice that they did not wish to take part in any
research or share their clinical data are excluded from
this phase.
For the total denominator population, invited to take
part at baseline, anonymised clinical data with patient
diagnostic information, prescribed drugs, blood tests and
investigations, referrals and linked healthcare activity
will be collected. This anonymised data archive covers a
total five year time-period (between 2006 and 2011)
from 3 years prior to the baseline survey to 12 months
after the 12 month follow-up survey (Figure 2).
Sample size
The pilot study was used to guide the sample size
needed. The primary outcome of the study is the mean
change in PCS score from baseline to 12-month follow-up. In order to compare the change in PCS score be-
tween the whole comorbid (OA and CVD) cohort and
the OA index cohort we estimated that at least 394
patients responding at 12 months per cohort were
needed (confidence level 0.05; power 80%) to detect a
between cohort effect size of 0.2. Based on expected
responses of 60% at baseline and 70% at 12 months, this
required 939 patients to be invited with comorbid OA
and CVD and 939 with OA alone. Assuming 75% con-
sent to medical record review, this number would also
give 423 people in each cohort responding at baseline
and consenting to record review. However, to maximize
numbers in the index CVD cohorts (hypertension, is-
chaemic heart disease and heart failure), OA index and
comorbid groups and in order to allow comparison be-
tween the CVD severity comorbid cohorts with their
related index CVD cohorts, we invited all eligible
patients with these conditions to participate. The excep-
tions were the index hypertension cohorts and index OA
cohorts where we randomly sampled patients stratified
by practice due to the large size of these groups. Simi-
larly, we also randomly sampled patients from the refer-
ence group without CVD or OA.
Analysis
Phase 1: Survey population
The initial analysis will use independent t-tests to com-
pare the OA and CVD comorbid cohorts with mean
change in PCS over the 12-month period. We will then
examine the influence of CVD severity, comorbidity and
baseline covariates on mean change in PCS score using
multiple linear regression methods, including cohort
group, anxiety and depression, Body Mass Index (BMI),
and socio-demographic characteristics (i.e. age, gender,
neighborhood level deprivation [58]) as explanatory vari-
ables. These analyses will be repeated with change in the
Mental Summary Component (MCS) score of the SF-12
as the outcome.
The monthly PCS scores from the SF-12 will be used
as time-dependent repeated outcomes in the 12-month
follow up period, to determine the association of base-
line measures and time on monthly PCS score. This ana-
lysis will use repeated measures multilevel modelling,
with a 2-level model (repeated PCS score within
patients) with the same explanatory variables as for the
12-month analysis.
Phase 2: Survey-consultation linkage
We will also determine cumulative onset of disability
defined on the basis of the generic and disease-specific
health measures. The rate of progression to severe dis-
ability in the comorbid groups will be estimated com-
pared to the other groups using Cox regression.
Attributable fractions for health status and clinical
Anonymised denominator cohort (total study population) N=9,676 
Survey responders cohort n=5,426 
Survey-consultation linkage consenters cohort n=4,030 
Baseline
Questionnaire 1 
Follow-up 
Questionnaire 12 
Baseline
Questionnaire 1 
Follow-up 
Questionnaire 12 
12 months consultations 12months consultations
12 months consultations/clinical data from GP records 12months consultations 
Total time-period 5 years (2006-2011) 
3 years consultations 
3 years consultations 
Monthly short questionnaires 
Figure 2 Comorbidity Cohort (2C) design.
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(age, gender, deprivation, obesity, consultation comor-
bidity) for onset or progression of disability will be
determined. We will also assess time to change in clin-
ical decisions.
Phase 3: Denominator population
We will compare consultation patterns and management
for the anonymised denominator cohort to the survey-
consultation cohort to assess generalisability of our find-
ings and estimate the likely extent of response bias.
Preliminary data
Initial data collection has already been completed and the
following data is presented to follow the sequence of sam-
pling stages in an epidemiological cohort study (Figure 2).
Denominator population
In the denominator cohort population, there were 9,676
people aged 40 years and over (Table 2) who wereidentified as baseline participants. The denominator study
groups were as follows: 2,535 (26%) without CVD or OA;
CVD index groups without OA – 1,322 (14%) with hyper-
tension, 2,036 (21%) with ischaemic heart disease, 259
(3%) with heart failure; 1,317 (13%) in OA index group
without CVD, and CVD groups with comorbid OA –
1,644 (17%) with hypertension, 490 (5%) with ischaemic
heart disease, 73 with heart failure (1%).
Reference cohort: The reference cohort without CVD
or OA (Table 3) was composed of the younger popula-
tion, and around 69% were aged 59 years or younger. It
had an equivalent number of men and women, and
around 20% in the top or bottom tertiles of deprivation.
Index CVD cohorts without OA: The youngest age
groups were in the hypertension cohort (30% aged
59 years and younger), and the oldest groups were in the
heart failure cohort (69% aged 70 years and over)
(Table 3). There were more men than women in both
the IHD and heart failure cohorts, and a quarter of the
heart failure cohort had the most deprived status.
Table 2 2C baseline cohorts
Disease
cohort
Cohort
ID
Denominator cohort
N = 9676 n
Responders cohort
n= 5426 n* (%)
Non-responders
cohort n =4250
n* (%)
Linkage consenters
cohort n =4030
n** (%)
-CVD -OA 0 2535 1165 (45.9) 1370 (54.1) 820 (70.4)
+Hyp -OA 1 1322 720 (54.5) 602 (45.5) 525 (72.9)
+IHD -OA 2 2036 1196 (58.7) 840 (41.3) 915 (76.5)
+HF -OA 3 259 149 (57.5) 110 (42.5) 108 (72.5)
-CVD+OA 4 1317 828 (62.9) 489 (37.1) 617 (74.5)
+Hyp+OA 5 1644 1017 (61.9) 627 (38.1) 773 (76.0)
+IHD+OA 6 490 305 (62.2) 185 (37.8) 237 (77.8)
+HF+OA 7 73 46 (63.0) 27 (37.0) 35 (76.1)
CVD=Cardiovascular disease, OA=Osteoarthritis, Hyp =Hypertension, IHD= Ischaemic heart disease, HF =Heart failure.
Disease categories (defined by study specific Read codes in the 3 years prior to baseline survey.
-CVD -OA= no record of CVD (hypertension, IHD or HF) condition or OA; -CVD +OA= record of OA but not CVD (hypertension, IHD or HF).
+Hyp -OA= record of hypertension without OA; +IHD -OA= record of IHD without OA; +HF -OA= record of HF without OA.
+Hyp+OA= record of hypertension and OA; +IHD+OA= record of IHD and OA; +HF +OA= record of HF and OA.
*percentage of denominator population; **percentage of responder population.
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was aged between 50 and 80 years of age, and there were
more women than men (Table 3). The age figures were
in contrast to the index CVD cohorts who had a higher
number in the age group 70 years and over, but the
deprivation figures were similar.
Comorbid CVD & OA cohort: The comorbid groups
were relatively older than the index groups and the age
proportion for the group 70 years and over were: 57% in
the hypertension comorbid group, 73% in the IHD
comorbid group and 93% in the heart failure comorbid
group (Table 3). There were more women than menTable 3 Socio-demographic characteristics of the 2C study de
Disease cohorts
Reference Index CVD cohorts
Factors -CVD -OA (0)
n = 2535
(%)
+Hyp -OA (1)
n = 1322
(%)
+IHD -OA (2)
n = 2036
(%)
+HF -
n =25
(%)
Age group
(years)
40-49 892 (35.2) 106 (8.0) 72 (3.5) 5 (1.9)
50-59 848 (33.5) 291 (22.0) 275 (13.5) 22 (8.5
60-69 513 (20.2) 416 (31.5) 617 (30.3) 54 (20
70-79 195 (7.7) 329 (24.9) 677 (33.3) 82 (31
80≥ 87 (3.4) 180 (13.6) 395 (19.4) 96 (37
Gender Men 1245 (49.1) 609 (46.1) 1334 (65.5) 142 (5
Women 1290 (50.9) 713 (53.9) 702 (34.5) 117 (4
Deprivation
Status*
Category 0
(most
affluent)
525 (20.8) 266 (20.2) 368 (18.1) 38 (14
Category 1 1521 (60.1) 786 (59.8) 1251 (61.6) 156 (6
Category 2
(most
deprived)
484 (19.1) 263 (20.0) 411 (20.3) 65 (25
CVD=Cardiovascular disease, OA =Osteoarthritis, Hyp =Hypertension, IHD= Ischaem
Multiple Deprivation score and available for 9,636 patients and ‘most affluent’ as thewith CVD and comorbid OA for all three groups, and
IHD comorbid group had relatively fewer numbers in
the top and bottom deprivation tertiles.
Survey participation and consent
In the baseline survey population, there were 5,426 (56%)
people aged 40 years and over who responded to the ques-
tionnaire. The lowest response was in the reference cohort
(46%) and the highest was in the comorbid heart failure
cohort (63%). The proportion of responders in the index
OA cohort and the CVD comorbid cohorts were higher
than the index CVD cohorts (Table 2).nominator population (n =9,676)
Index OA cohort CVD comorbid cohorts
OA (3)
9
-CVD+OA (4)
n = 1317
(%)
+Hyp+OA (5)
n = 1644
(%)
+IHD+OA (6)
n = 490
(%)
+HF+OA (7)
n = 73
(%)
138 (10.4) 33 (2.0) 4 (0.8) 0 (0)
) 309 (23.5) 172 (10.4) 22 (4.5) 1 (1.4)
.8) 445 (33.8) 499 (30.4) 106 (21.7) 4 (5.5)
.7) 278 (21.1) 554 (33.7) 203 (41.4) 23 (31.5)
.1) 147 (11.2) 386 (23.5) 155 (31.6) 45 (61.6)
4.8) 563 (42.7) 611 (37.2) 205 (41.8) 31 (42.5)
5.2) 754 (57.3) 1033 (62.8) 285 (58.2) 42 (57.5)
.7) 267 (20.3) 327 (20.0) 86 (17.7) 13 (18.3)
0.2) 808 (61.6) 980 (60.0) 310 (63.9) 43 (60.6)
.1) 237 (18.1) 327 (20.0) 89 (18.4) 15 (21.1)
ic heart disease, HF =Heart failure. *Deprivation status is based on Index of
top 20% of the sample and ‘most deprived’ as the bottom 20% of the sample.
Table 4 Socio-demographic characteristics of baseline responders stratified by study groups (n =5,426)
Disease cohorts
Reference Index CVD cohorts Index OA cohort CVD comorbid cohorts
Factors -CVD -OA (0)
n = 1165
(%)
+Hyp -OA (1)
n = 720
(%)
+IHD -OA (2)
n = 1196
(%)
+HF -OA (3)
n =149
(%)
-CVD+OA (4)
n = 828
(%)
+Hyp+OA (5)
n = 1017
(%)
+IHD+OA (6)
n = 305
(%)
+HF+OA (7)
n = 46
(%)
Age group
(years)
40-49 313 (26.8) 33 (4.6) 21 (1.7) 3 (2.0) 59 (7.1) 9 (0.9) 1 (0.3) 0 (0)
50-59 413 (35.5) 132 (18.3) 127 (10.6) 9 (6.1) 180 (21.7) 92 (9.0) 11 (3.6) 0 (0)
60-69 282 (24.2) 239 (33.2) 369 (30.9) 26 (17.4) 312 (37.7) 318 (31.3) 64 (21.0) 3 (6.5)
70-79 119 (10.2) 219 (30.4) 446 (37.3) 53 (35.6) 180 (21.8) 369 (36.3) 136 (44.6) 16 (34.8)
80≥ 38 (3.3) 97 (13.5) 233 (19.5) 58 (38.9) 97 (11.7) 229 (22.5) 93 (30.5) 27 (58.7)
Gender Men 547 (47.0) 324 (45.0) 807 (67.5) 89 (59.7) 332 (40.1) 391 (38.4) 140 (45.9) 23 (50.0)
Women 618 (53.0) 395 (55.0) 389 (32.5) 60 (40.3) 496 (59.9) 626 (61.6) 165 (54.1) 23 (50.0)
Deprivation
Status*
Category 0
(most
affluent)
279 (24.0) 155 (21.7) 243 (20.4) 23 (15.4) 168 (20.4) 222 (22.0) 59 (19.6) 8 (18.2)
Category 1 712 (61.2) 425 (59.4) 732 (61.4) 90 (60.4) 521 (63.2) 605 (59.9) 190 (63.1) 27 (61.3)
Category 2
(most
deprived)
173 (14.8) 135 (18.9) 217 (18.2) 36 (24.2) 135 (16.4) 183 (18.1) 52 (17.3) 9 (20.5)
CVD=Cardiovascular disease, OA =Osteoarthritis, Hyp =Hypertension, IHD= Ischaemic heart disease, HF =Heart failure. *Deprivation status is based on Index of
Multiple Deprivation score and available for 5,399 patients and ‘most affluent’ as the top 20% of the sample and ‘most deprived’ as the bottom 20% of the sample.
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of age, gender and deprivation characteristics, compared
to the denominator population (Table 3 and 4). When
comparing the responder and non-responder groups
(Tables 4 and 5), non-responders were likely to be the
younger groups, women and those people with the most
deprived status. In the reference cohort, 74% of the non-Table 5 Socio-demographic characteristics of baseline non-re
Disease cohorts (Cohort ID)
Reference Index CVD groups
Factors -CVD -OA (0)
n = 1370
(%)
+Hyp -OA (1)
n = 602
(%)
+IHD -OA (2)
n = 840
(%)
+HF -
n = 11
%)
Age group
(years)
40-49 579 (42.2) 73 (12.1) 51 (6.1) 2 (1.8)
50-59 435 (31.8) 159 (26.4) 148 (17.6) 13 (11
60-69 231 (16.9) 177 (29.4) 248 (29.5) 28 (25
70-79 76 (5.5) 110 (18.3) 231 (27.5) 29 (26
80≥ 49 (3.6) 83 (13.8) 162 (19.3) 38 (34
Gender Men 698 (50.9) 285 (47.3) 527 (62.7) 53 (48
Women 672 (49.1) 317 (52.7) 313 (37.3) 57 (51
Deprivation
Status*
Category 0
(most
affluent)
246 (18.0) 111 (18.5) 125 (14.9) 15 (13
Category 1 809 (59.2) 361 (60.2) 519 (61.9) 66 (60
Category 2
(most
deprived)
311 (22.8) 128 (21.3) 194 (23.2) 29 (26
CVD=Cardiovascular disease, OA =Osteoarthritis, Hyp =Hypertension, IHD= Ischaem
Multiple Deprivation score and available for 4,327 patients and ‘most affluent’ as theresponder group were 59 years or younger. The age pro-
portions of the index hypertension and index OA cohort
were similar, but the proportions of age groups 70 years
and over were higher in index IHD (47%) and heart fail-
ure (61%) cohorts, and highest in the IHD (70%) and
heart failure (93%) comorbid cohorts. Apart from the
reference cohort and the index IHD cohort, there weresponders stratified by study groups (n = 4,250)
Index OA Groups CVD comorbid groups
OA (3)
0 (
-CVD+OA (4)
n = 489
(%)
+Hyp+OA (5)
n = 627
(%)
+IHD+OA (6)
n = 185
(%)
+HF+OA 7)
n = 27
(%)
79 (16.2) 24 (3.8) 3 (1.6) 0 (0)
.8) 129 (26.4) 80 (12.8) 11 (5.9) 1 (3.7)
.5) 133 (27.2) 181 (2.9) 42 (22.7) 1 (3.7)
.4) 98 (20.0) 185 (29.5) 68 (36.8) 7 (25.9)
.5) 50 (10.2) 157 (25.0) 61 (33.0) 18 (66.7)
.2) 231 (47.2) 220 (35.1) 65 (35.1) 8 (29.6)
.8) 258 (52.8) 407 (64.9) 120 (64.9) 19 (70.4)
.6) 99 (20.3) 105 (16.8) 27 (14.7) 5 (18.5)
.0) 287 (58.8) 375 (60.1) 120 (65.2) 16 (59.3)
.4) 102 (20.9) 144 (23.1) 37 (20.1) 6 (22.2)
ic heart disease, HF =Heart failure. *Deprivation status is based on Index of
top 20% of the sample and ‘most deprived’ as the bottom 20% of the sample.
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http://www.biomedcentral.com/1472-6963/12/295more women than men non-responders, and around a
quarter of the most deprived groups were non-
responders in all study cohorts.
Of the survey responders, 4,030 (74%) gave permission
to access and link their clinical records (Table 2), and
this linked clinical data will be anonymised for the pur-
poses of analyses. The lowest consent proportion was in
the reference group (70%) and the highest in the CVD
comorbid groups (76%).
Discussion
There are very few comorbidity cohort studies [59] and
this is the first study of its kind which has been con-
structed with a priori hypotheses, identifying two com-
mon chronic diseases (CVD and OA) in the general
practice population, and testing their interaction in rela-
tion to self-reported health and health care outcomes.
The innovative epidemiological design incorporates
comorbid interaction, interaction as influenced by sever-
ity (in this example of CVD), and potential cohort im-
pact both in the short-term and longer-term. The
innovative methodological design also incorporates a de-
nominator cohort, from which a survey population was
sampled, allowing the assessment of selection and data
issues. The linkage between survey data and consultation
data provides the investigation of population symptoms
and health, and their impact on short and longer-term
healthcare outcomes.
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